This site is intended for U.S. animal healthcare professionals
CYTOPOINT® can be used even in dogs with challenging comorbidities1
EXELAND, male, age 9 years, Labrador Retriever
Veterinarian: Dr Lisa Reiter, University of Minnesota College of Veterinary Medicine, Minneapolis, MN
Exeland suffers from both blastomycosis and canine atopic dermatitis
Presentation and history
Exeland had suffered all his life from chronic year-round canine atopic dermatitis, with severe seasonal exacerbations. Antihistamines, glucocorticoids (oral and injectable), cyclosporine, allergen-specific immunotherapy and a strict elimination diet had failed to control his disease.
Exeland’s clinical picture became more complicated when he was diagnosed with blastomycosis with severe pulmonary and ocular infiltration and secondary bacterial pneumonia. He was prescribed various antifungals, including itraconazole, parenteral amphotericin B and voriconazole.
When Exeland presented to Dr Reiter, he had generalized superficial bacterial folliculitis and bilateral Malassezia otitis. He was receiving 10 mg prednisone every other day; despite this, Dr Reiter rated his pruritus 10/10.
Exeland’s owner has a debilitating condition that affects his manual dexterity and makes regular pilling challenging, and Exeland’s treatments and illness were becoming both mentally and physically overwhelming for him. For both owner and dog, Exeland’s refractory itch was having a severe negative impact on quality of life.
Exeland remained controlled for nearly 3 months after one injection
Exeland’s treatment team was reluctant to increase the prednisone dose above 10 mg every other day due to Exeland’s systemic fungal disease. Because of Exeland’s serious infection, a number of potential treatments were contraindicated. Dr Reiter decided to give Exeland an injection of CYTOPOINT.
CYTOPOINT treatment result
Exeland’s owner called 2 days after the initial injection to report that Exeland’s itch was 0/10. Exeland’s itch remained controlled for nearly 3 months after the first injection. Dr Reiter reports that Exeland’s blastomycosis continues to improve clinically and his Blastomyces antigen urine titer continues to decrease. Exeland has remained free of skin and ear infections.
“This [product] truly saved both [the owner’s] and my patient’s lives! I don’t know what I would have done without having access to this amazing [product]. Thank you, Zoetis!” — Dr Lisa Reiter, 6/30/16
Indication:CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.
Reference: 1. Data on file, CYTOPOINT Case Studies, Zoetis Inc.
Testimonials represent individual experience only, and the experiences and opinions may be unique to the patient and the speaker. Individual results may vary considering the unique characteristics of the patient.
This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.